Published in Clin Vaccine Immunol on July 18, 2007
A multiplex assay for the simultaneous detection of antibodies against 15 Plasmodium falciparum and Anopheles gambiae saliva antigens. Malar J (2010) 1.11
A novel assay to measure B cell responses to keyhole limpet haemocyanin vaccination in healthy volunteers and subjects with systemic lupus erythematosus. Br J Clin Pharmacol (2013) 0.87
Allergen micro-bead array for IgE detection: a feasibility study using allergenic molecules tested on a flexible multiplex flow cytometric immunoassay. PLoS One (2012) 0.81
Exogenous rhTRX reduces lipid accumulation under LPS-induced inflammation. Exp Mol Med (2014) 0.75
Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin. N Engl J Med (2002) 7.00
Naturally occurring antibodies against nine common antigens in human sera. I. Detection, isolation and characterization. J Immunol (1982) 4.21
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods (2004) 3.53
Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol (2004) 3.13
Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18. Clin Diagn Lab Immunol (2005) 2.72
Lessons from Eprex for biogeneric firms. Nat Biotechnol (2003) 2.22
Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol (2006) 1.98
Immune responses to therapeutic proteins in humans--clinical significance, assessment and prediction. Curr Pharm Biotechnol (2002) 1.81
Erythropoiesis-stimulating agents and antibody-mediated pure red-cell aplasia: here are we now and where do we go from here? Nephrol Dial Transplant (2004) 1.59
More useful maleimide compounds for the conjugation of Fab' to horseradish peroxidase through thiol groups in the hinge. J Appl Biochem (1984) 1.38
The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int (2005) 1.31
Human immune response to recombinant human proteins. J Pharm Sci (2001) 1.23
Evaluation of the BioPlex 2200 ANA screen: analysis of 510 healthy subjects: incidence of natural/predictive autoantibodies. Ann N Y Acad Sci (2005) 1.22
Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant (2005) 1.16
Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract (2004) 1.01
Importance of biologic follow-ons: experience with EPO. Best Pract Res Clin Haematol (2005) 0.93
Erythropoietin-induced, antibody-mediated pure red cell aplasia. Eur J Clin Invest (2005) 0.92
Multiplexed particle-based anti-granulocyte macrophage colony stimulating factor assay used as pulmonary diagnostic test. Clin Diagn Lab Immunol (2005) 0.89
Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol Dial Transplant (2005) 0.88
Reaction to the paper: interaction of polysorbate 80 with erythropoietin: a case study in protein-surfactant interactions. Pharm Res (2006) 0.85
Development and validation of a cell-based bioassay for the detection of neutralizing antibodies against recombinant human erythropoietin in clinical studies. J Immunol Methods (2004) 0.80
Validation of the BIACORE 3000 platform for detection of antibodies against erythropoietic agents in human serum samples. Curr Med Res Opin (2003) 0.79
Use of biosensors to monitor the immune response. Dev Biol (Basel) (2002) 0.78
A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature (2005) 18.43
Mutation in TET2 in myeloid cancers. N Engl J Med (2009) 16.07
Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods (2004) 3.53
Pure red-cell aplasia and epoetin therapy. N Engl J Med (2004) 3.49
A peptide-based erythropoietin-receptor agonist for pure red-cell aplasia. N Engl J Med (2009) 3.37
Cytometric bead array: a multiplexed assay platform with applications in various areas of biology. Clin Immunol (2004) 3.13
Public biotech 2010--the numbers. Nat Biotechnol (2011) 2.88
Antibody-mediated pure red cell aplasia in chronic kidney disease patients receiving erythropoiesis-stimulating agents: new insights. Kidney Int (2012) 2.38
Reassessments of ESAs for cancer treatment in the US and Europe. Oncology (Williston Park) (2010) 2.22
The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. Blood (2008) 2.21
Infected facial tissue fillers: case series and review of the literature. J Oral Maxillofac Surg (2012) 2.06
Determinants of quality of life in patients with psoriasis: a study from the US population. J Am Acad Dermatol (2004) 1.94
The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera. Blood (2007) 1.83
Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol (2004) 1.81
Epoetin-associated pure red cell aplasia: past, present, and future considerations. Transfusion (2008) 1.73
Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood (2006) 1.71
Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol (2003) 1.71
Iron administration before stem cell harvest enables MR imaging tracking after transplantation. Radiology (2013) 1.70
The prevalence of psoriasis in African Americans: results from a population-based study. J Am Acad Dermatol (2005) 1.68
Comparing ELISA and surface plasmon resonance for assessing clinical immunogenicity of panitumumab. J Immunol (2007) 1.68
Molecular aspects of myeloproliferative neoplasms. Int J Hematol (2010) 1.67
Epratuzumab, a humanized monoclonal antibody targeting CD22: characterization of in vitro properties. Clin Cancer Res (2003) 1.61
Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods (2008) 1.60
Antibody-mediated pure red cell aplasia in a dialysis patient receiving darbepoetin alfa as the sole erythropoietic agent. Nephrol Dial Transplant (2006) 1.56
Multiple signaling pathways are involved in erythropoietin-independent differentiation of erythroid progenitors in polycythemia vera. Exp Hematol (2004) 1.46
Arsenic trioxide in patients with myelodysplastic syndromes: a phase II multicenter study. J Clin Oncol (2006) 1.43
Recommendations for the design, optimization, and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods (2007) 1.42
Treatment of erythropoietin-induced pure red cell aplasia: a retrospective study. Lancet (2004) 1.41
Immunogenicity of panitumumab in combination chemotherapy clinical trials. BMC Clin Pharmacol (2011) 1.40
Public companies get creative in raising finance. Nat Biotechnol (2010) 1.39
2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. Pediatr Blood Cancer (2009) 1.39
Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun (2007) 1.37
Evidence that the JAK2 G1849T (V617F) mutation occurs in a lymphomyeloid progenitor in polycythemia vera and idiopathic myelofibrosis. Blood (2006) 1.35
Performance of locomotion and foot grasping following a unilateral thoracic corticospinal tract lesion in monkeys (Macaca mulatta). Brain (2005) 1.32
Tungsten-induced denaturation and aggregation of epoetin alfa during primary packaging as a cause of immunogenicity. Pharm Res (2011) 1.31
The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int (2005) 1.31
Bevacizumab, oxaliplatin, and capecitabine with radiation therapy in rectal cancer: Phase I trial results. Int J Radiat Oncol Biol Phys (2007) 1.28
Racial differences in pelvic morphology among asymptomatic nulliparous women as seen on three-dimensional magnetic resonance images. Am J Obstet Gynecol (2005) 1.28
Kinematic and EMG determinants in quadrupedal locomotion of a non-human primate (Rhesus). J Neurophysiol (2005) 1.27
Bacterial biofilms in surgical specimens of patients with chronic rhinosinusitis. Laryngoscope (2005) 1.25
Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide. Diabetes (2002) 1.23
An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen. J Immunol Methods (2005) 1.23
Genetic basis of congenital erythrocytosis: mutation update and online databases. Hum Mutat (2013) 1.18
Autoimmune anemia in macaques following erythropoietin gene therapy. Blood (2004) 1.16
Epoetin-associated pure red cell aplasia in patients with chronic kidney disease: solving the mystery. Nephrol Dial Transplant (2005) 1.16
Pure red-cell aplasia due to anti-erythropoietin antibodies. Nephrol Dial Transplant (2003) 1.15
Prostate epithelial cell fate. Differentiation (2008) 1.13
Overexpression of FKBP51 in idiopathic myelofibrosis regulates the growth factor independence of megakaryocyte progenitors. Blood (2002) 1.12
Pure red cell aplasia induced by erythropoiesis-stimulating agents. Clin J Am Soc Nephrol (2008) 1.11
Hematide is immunologically distinct from erythropoietin and corrects anemia induced by antierythropoietin antibodies in a rat pure red cell aplasia model. Exp Hematol (2007) 1.09
Beta ig-h3 interacts directly with biglycan and decorin, promotes collagen VI aggregation, and participates in ternary complexing with these macromolecules. J Biol Chem (2006) 1.08
A JAK2 mutation in myeloproliferative disorders: pathogenesis and therapeutic and scientific prospects. Trends Mol Med (2005) 1.08
Anatomy of the intrinsic hand muscles revisited: part I. Interossei. Plast Reconstr Surg (2002) 1.06
Comparison of a high-throughput high-content intracellular Leishmania donovani assay with an axenic amastigote assay. Antimicrob Agents Chemother (2013) 1.06
Accuracy of abdominal radiography in acute small-bowel obstruction: does reviewer experience matter? AJR Am J Roentgenol (2007) 1.06
Selective reduction of JAK2V617F-dependent cell growth by siRNA/shRNA and its reversal by cytokines. Blood (2009) 1.05
Nitrite reductase and nitric-oxide synthase activity of the mitochondrial molybdopterin enzymes mARC1 and mARC2. J Biol Chem (2014) 1.05
Timing and determinants of erythropoietin deficiency in chronic kidney disease. Clin J Am Soc Nephrol (2011) 1.05
Rheumatoid factor interference in immunogenicity assays for human monoclonal antibody therapeutics. J Immunol Methods (2010) 1.05
Immunogenicity of recombinant human proteins: causes and consequences. J Neurol (2004) 1.05
Identification and inhibition of drug target interference in immunogenicity assays. J Immunol Methods (2010) 1.04
Small-bowel obstruction: coronal reformations from isotropic voxels at 16-section multi-detector row CT. Radiology (2005) 1.03
It's a trap! Clinical similarities and subtle ECG differences between takotsubo cardiomyopathy and myocardial infarction. J Gen Intern Med (2008) 1.02
Regulation of autoimmune arthritis by the pro-inflammatory cytokine interferon-gamma. Clin Immunol (2008) 1.02
Occupational hazards of interventional cardiologists: prevalence of orthopedic health problems in contemporary practice. Catheter Cardiovasc Interv (2004) 1.01
Evaluation of methods to detect and characterize antibodies against recombinant human erythropoietin. Nephron Clin Pract (2004) 1.01
Immunogenicity testing by electrochemiluminescent detection for antibodies directed against therapeutic human monoclonal antibodies. Clin Chem (2005) 0.99
The fallacies of hope: will we discover new antibiotics to combat pathogenic bacteria in time? FEMS Microbiol Rev (2006) 0.99
Role of tyrosine kinases and phosphatases in polycythemia vera. Semin Hematol (2005) 0.99
MDCT of patients with acute abdominal pain: a new perspective using coronal reformations from submillimeter isotropic voxels. AJR Am J Roentgenol (2004) 0.99
Epitope characterization of pre-existing and developing antibodies to an aglycosylated monoclonal antibody therapeutic of G1m17,1 allotype. J Immunol Methods (2012) 0.97
Studies on the antimicrobial properties of N-acylated ciprofloxacins. Bioorg Med Chem Lett (2012) 0.97
Finite element modeling reveals complex strain mechanics in the aponeuroses of contracting skeletal muscle. J Biomech (2010) 0.97
The development and validation of a sensitive, dual-flow cell, SPR-based biosensor immunoassay for the detection, semi-quantitation, and characterization of antibodies to darbepoetin alfa and epoetin alfa in human serum. J Pharm Biomed Anal (2008) 0.96
Adaptations for finding irregularly shaped disease clusters. Int J Health Geogr (2007) 0.96
Development of a maturing T-cell-mediated immune response in patients with idiopathic Parkinson's disease receiving r-metHuGDNF via continuous intraputaminal infusion. J Clin Immunol (2007) 0.96
Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol (2008) 0.95
Identifying the estrogen receptor coactivator PELP1 in autophagosomes. Cancer Res (2007) 0.95
Adrenal nodules at FDG PET/CT in patients known to have or suspected of having lung cancer: a proposal for an efficient diagnostic algorithm. Radiology (2009) 0.94
Distinct deregulation of the hypoxia inducible factor by PHD2 mutants identified in germline DNA of patients with polycythemia. Haematologica (2011) 0.92
Afferent input modulates neurotrophins and synaptic plasticity in the spinal cord. J Neurophysiol (2004) 0.92
2 billion euro IMI launched with European pharma. Nat Biotechnol (2008) 0.90
Late-onset neutropenia following rituximab results from a hematopoietic lineage competition due to an excessive BAFF-induced B-cell recovery. Haematologica (2007) 0.90
Early high-dose erythropoietin therapy and hypothermia after out-of-hospital cardiac arrest: a matched control study. Resuscitation (2007) 0.90
WHO guidelines presage US biosimilars legislation? Nat Biotechnol (2009) 0.90
Re-challenging patients who developed pure red cell aplasia with epoetin: can it be done? Nephrol Dial Transplant (2004) 0.89
Doubts linger over Mexican corn analysis. Nat Biotechnol (2002) 0.89
The detection of anti-erythropoietin antibodies in human serum and plasma. Part I. Validation of the protocol for a radioimmunoprecipitation assay. J Immunol Methods (2003) 0.89
Multi-detector row CT of the small bowel: peak enhancement temporal window--initial experience. Radiology (2007) 0.89
"Makes you proud to be black eh?": reflections on meaningful indigenous research participation. Int J Equity Health (2012) 0.89
Role of interventional procedures in obstetrics/gynecology. Radiol Clin North Am (2013) 0.89
Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures. Nephrol Dial Transplant (2005) 0.88
Antibody-mediated pure red cell aplasia (PRCA) treatment and re-treatment: multiple options. Nephrol Dial Transplant (2005) 0.88
Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol (2005) 0.87
Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists. Bioorg Med Chem Lett (2007) 0.87
Studies on the immunomodulatory effect of extract of Cyanodon dactylon in shrimp, Penaeus monodon, and its efficacy to protect the shrimp from white spot syndrome virus (WSSV). Fish Shellfish Immunol (2008) 0.87
Pseudoaneurysm of the uterine artery after an uncomplicated spontaneous vaginal delivery. J Ultrasound Med (2006) 0.87
Strategy to confirm the presence of anti-erythropoietin neutralizing antibodies in human serum. J Pharm Biomed Anal (2011) 0.86